Lysogene raises $25M in Paris IPO; Chan Zuckerberg Biohub starts handing out $50M

Karen Aiach

• The gene therapy company Lysogene has raised $25 million from an IPO on Euronext Paris designed to fund its R&D work. “This IPO will enable us to pursue the development of two drugs to treat two polysdisabling, devastating and deadly diseases of the central nervous system, which start in infancy and lead to the patients premature death,” said CEO Karen Aiach. “By focusing directly on the cause, our treatments aim to cure these diseases the medical needs of which are largely unsatisfied and currently uncovered.

• The Chan Zuckerberg Biohub launched by FaceBook mogul Mark Zuckerberg and his wife has begun to dole out $50 million to 47 investigators who won 5 years of financial support for their research projects. The Biohub brings together Bay Area universities to collaborate on new research initiatives.

• The FTC has sued Shire ViroPharma for the tactics it used in fighting off a generic competitor to its antibiotic Vancocin HCI.

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy